Pharmacogenomics is the study of how human genetic variation affects an individual’s response to drug therapies. Understanding a patient’s genetic background allows a physician to predict how a prescribed drug will relate with that patient, giving the clinician insight into not only clinical efficacy, but also potential undesired drug reactions.
- Biologic enzymes found in our liver act upon certain target substrates and then trigger a metabolic chain reaction.
- This data can then be used to help physicians avoid drugs that would be inefficiently metabolized and guide them towards drugs that use more robust metabolic pathways.
FDA studies estimate that 7% of hospitalized patients have a serious adverse drug reaction with a fatality rate of 0.32%.
By isolating and examining the regions of a patient’s DNA that code for the enzymes of interest, we can provide the following answers:
Patients have differences in DNA that impact drug metabolism which may increase their likelihood of an adverse drug reaction:
Who To Test?
Personalized Genomics advises pharmacogenomics testing for patients that meet one or more of the following conditions: